Page 193 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild to moderately severe
Groups similar at baseline: Yes

rivastigmine 1-4 mg/d placebo rivastigmine 6-12 mg/d NR NR NR NR NR NR NR NR NR 23.29 23.57 23.87 54.1 55.22 53.8 Primary Outcome Measures: ADAS-Cog; PDS; CIBIC Secondary Outcome Measures: MMSE; GDS Timing of assessments: Primary outcome measures at baseline and weeks 12, 18 and 26; secondary outcome measures at baseline and week 26 Health Outcome Measures: Scores on PDS improved in patients taking high dose RIV when compared with placebo, P < 0.05 (LOCF analysis); no significant difference observed between low dose RIV and placebo, P

• • • • •

Final Report Update 1 Authors: Rösler et al. Year: 1999 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Baseline ADAS-Cog • Baseline PDS • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs